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Objectives: Data on the consumption of macrolides, lincosamides and streptogramins (MLS) in the community
were collected from 30 EU/European Economic Area (EEA) countries over two decades. This article reviews tem-
poral trends, seasonal variation, presence of change-points and changes in composition of the main subgroups
of MLS.
Methods: For the period 1997–2017, data on consumption of MLS, i.e. ATC group J01F, in the community
and aggregated at the level of the active substance, were collected using the WHO ATC/DDD methodology (ATC/
DDD index 2019). Consumption was expressed in DDD per 1000 inhabitants per day and in packages per 1000
inhabitants per day. Consumption of MLS was analysed and presented as trends, seasonal variation, presence of
change-points and compositional changes, using a classification based on mean plasma elimination half-life for
macrolides.
Results: In 2017, consumption of MLS in the community expressed in DDD per 1000 inhabitants per day varied
by a factor of 13 between countries with the highest (Greece) and the lowest (Sweden) consumption.
Consumption of MLS did not change significantly up to 2003, after which it significantly increased up to 2007.
No significant change was observed after 2007. Consumption of MLS showed high seasonal variation. The
proportional consumption of long-acting macrolides significantly increased over time compared with that of
intermediate-acting macrolides, and proportional consumption of the latter increased compared with that of
short-acting macrolides.
Conclusions: Consumption of MLS did not change significantly over time during 2007–2017, while the propor-
tional consumption of long-acting macrolides increased. Seasonal variation remained high, which suggests that
MLS are still prescribed inappropriately in many countries.
Introduction
This article presents data from the European Surveillance of
Antimicrobial Consumption Network (ESAC-Net,1 formerly
ESAC) on community (i.e. primary care sector) consumption of
macrolides, lincosamides and streptogramins (MLS) for 30
EU/European Economic Area (EEA) countries in 2017 (Table 1).
It updates previous ESAC studies published in 2006 and 2011,
and in doing so it provides updated comparable and reliable in-
formation on antibiotic consumption that can aid in fighting
the global problem of antimicrobial resistance.2,3 In 2017, con-
sumption of MLS represented 16.1% of antibiotic consumption
in the community.4 As in the previous series, a classification of
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macrolides based on their mean plasma elimination half-life
was adopted. The objective of this study was to analyse
temporal trends, seasonal variation and the presence of
change-points in consumption of MLS in the community for the
period 1997–2017, as well as to analyse the composition of
consumption of MLS over time.
Methods
The methods for collecting and analysing the data are described in the
introductory article of this series.5 In summary, data on consumption of
MLS, i.e. ATC group J01F and aggregated at the level of the active sub-
stance, were collected using the WHO ATC/DDD methodology (ATC/DDD
index 20195) and expressed in DDD per 1000 inhabitants per day. In add-
ition, where data were available, consumption of MLS was also expressed in
packages per 1000 inhabitants per day. For macrolides, a classification
according to the mean plasma elimination half-life, subdividing macrolides
into short- (half-life <4 h), intermediate- (half-life from 4 to 24 h) and
long-acting macrolides (half-life >24 h), was used to assess macrolide
consumption in the community in more detail (Table 1).
The evolution of the number of DDD per package over time was
assessed using a linear mixed model. The temporal trend, seasonal vari-
ation and presence of change-points in consumption of MLS were assessed
using a non-linear change-point mixed model fitted to quarterly data
expressed in DDD per 1000 inhabitants per day from 1997 to 2017.6
The relative proportions of the main subgroups were assessed through a
compositional data analysis modelling yearly data expressed in DDD per
1000 inhabitants per day from 1997 to 2017.7
Results
An overview of consumption of MLS (ATC J01F) in the community,
expressed in DDD and packages per 1000 inhabitants per day for
all participating countries between 1997 and 2017 is available as
Supplementary data at JAC Online (Tables S1 and S2, respectively).
Consumption of MLS in the community in 2017
In 2017, three substances accounted for 90% of the consumption
of MLS in the community expressed in DDD per 1000 inhabitants
per day: clarithromycin (45.8% in 2017 compared with 54.2%
in 2009), azithromycin (35.5% in 2017 compared with 23.3% in
2009) and clindamycin (10.3% in 2017 compared with 6.6% in
2009) (Table 1).
Figure 1 shows the consumption of MLS in the community
expressed in DDD per 1000 inhabitants per day for 30 EU/EEA
countries in 2017. Consumption of MLS in the community varied by
a factor of 13 between countries with the highest (6.98 DDD per
1000 inhabitants per day in Greece) and the lowest (0.54 DDD per
1000 inhabitants per day in Sweden) consumption, which was
lower than in 2009 (factor of 18, from 11.54 DDD per 1000 inhabi-
tants per day in Greece to 0.63 DDD per 1000 inhabitants per day
in Sweden). Inter-country variations for macrolides (J01FA) were
high for short-acting macrolides, intermediate-acting macrolides
and long-acting macrolides. While lincosamide (J01FF; mainly clin-
damycin) consumption was reported in all countries, streptogra-
min (J01FG, pristinamycin) consumption in the community was
only reported in France (Table S1).
In 2017, short-acting macrolides (mainly erythromycin) were
the most consumed subgroup of MLS in Norway (>40% of con-
sumption of MLS in the community), and accounted for >20% of
consumption in the United Kingdom and >10% in Iceland and
Sweden. Intermediate-acting macrolides (mainly clarithromycin,
except Denmark mainly roxithromycin) were the most consumed
Table 1. Classification of macrolides, lincosamides and streptogramins (J01F; ATC/DDD index 2019)
Macrolides
Short-acting Intermediate-acting Long-acting
J01FA01 Erythromycina J01FA06 Roxithromycin J01FA10 Azithromycina
J01FA02 Spiramycin J01FA07 Josamycin J01FA13 Dirithromycin
J01FA03 Midecamycin J01FA09 Clarithromycina
J01FA05 Oleandomycinb J01FA14 Flurithromycin
J01FA08 Troleandomycinb J01FA15 Telithromycin








Bold type indicates that consumption was part of the top 90% of the community consumption of macrolide, lincosamide and streptogramin (MLS)
antibiotics (J01F) in 28 EU/EEA countries in 2017; Italic type indicates that no consumption of this MLS antibiotic was reported in 28 EU/EEA countries
in 2017.
aConsumption was part of the top 90% of the community consumption of MLS antibiotics (J01F) in 30 EU/EEA countries in 2009.
bNo consumption of this MLS antibiotic was reported in 30 EU/EEA countries in 2009.
cThis MLS antibiotic was not included in the ATC/DDD index in 2009 and was therefore not reported in 2009.








ent_2/ii30/6328676 by 81728827 user on 20 O
ctober 2021
subgroup of MLS in Austria, Bulgaria, Cyprus (total care data, i.e.
community and hospital sector combined), Czechia, Denmark,
Estonia, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania,
Malta, Portugal, Romania (total care data), Slovakia and the United
Kingdom. Clarithromycin and roxithromycin consumption repre-
sented >30% of consumption of MLS in Belgium, Croatia, Hungary,
Poland and Slovenia. Long-acting macrolides were the most con-
sumed subgroup of MLS in Belgium, Croatia, Finland, Hungary,
Iceland, Luxembourg, the Netherlands, Poland, Slovenia and
Spain. Compared with 2009, the proportional consumption of
long-acting macrolides increased in most countries. Lincosamides
were the most consumed MLS in Sweden and represented >20%
of the consumption of MLS in the community in Austria, Finland,
Germany, Hungary and Luxembourg.
Figure 2 shows consumption of MLS in the community
expressed in packages per 1000 inhabitants per day for 20 EU/EEA
countries in 2017. France ranked 9th for its consumption of MLS in
DDD per 1000 inhabitants per day and 4th in packages per 1000
inhabitants per day (Table 2). The number of DDD per package
ranged from 4.8 in France to 9.6 in Greece. In the EU/EEA countries,
the number of DDD per package did not change significantly over
time during 1997–2017.
Longitudinal data analysis, 1997–2017
The best model fit was obtained for a model including two
change-points: one in the last quarter of 2003 and another in the
second quarter of 2007. The final model fits the observed data
well (Figure S1). The longitudinal data analysis estimated an aver-
age consumption of MLS in the EU/EEA of 2.73 (SE 0.39) DDD per
1000 inhabitants per day in the first quarter of 1997. Consumption
of MLS did not change significantly (#0.0004, SE 0.006, DDD per
1000 inhabitants per day per quarter) between 1997 and the
last quarter of 2003. After this first change-point, consumption of
MLS significantly increased (!0.033, SE 0.015, DDD per 1000
inhabitants per day per quarter). After the second change point,
consumption of MLS did not change significantly (!0.0028,
SE 0.017, DDD per 1000 inhabitants per day per quarter; Figure 3).
The longitudinal analysis showed significant seasonal variation
with an amplitude of 0.98 (SE 0.21) DDD per 1000 inhabitants per
day, which did not change significantly over time (#0.0006, SE
0.0006, DDD per 1000 inhabitants per day per quarter).
Based on the fitted model, consumption of MLS in 2017 was
significantly higher than average in Austria, Belgium, Greece and
Italy, and significantly lower than average in Croatia, Estonia,
Finland, Iceland, Lithuania, the Netherlands, Poland and Sweden
(observed profiles shown in Figures S2 and S3). The seasonal vari-
ation was significantly larger than average in Greece, Italy and
Slovakia and significantly smaller than average in Denmark,
Finland, Iceland, the Netherlands, Sweden and the United
Kingdom. The decrease in consumption of MLS between 1997 and
the last quarter of 2003 was significantly larger than average in
Austria, Belgium, Spain and the United Kingdom. The increase in
consumption of MLS between 2004 and the second quarter of
2007 was significantly larger than average in Croatia, Estonia,
Ireland, Slovakia and Lithuania.
Table S1 provides an overview of the trends in consumption
of MLS in the participating countries between 1997 and 2017.
Consumption of MLS decreased in most countries, in particular in


























































































































































Figure 1. Consumption of macrolides, lincosamides and streptogramins (ATC J01F) in the community, expressed in DDD (ATC/DDD index 2019) per
1000 inhabitants per day, 30 EU/EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania,









ent_2/ii30/6328676 by 81728827 user on 20 O
ctober 2021
observed for Luxembourg, Spain and Latvia. The seasonal variation
in consumption of MLS is shown in Figures S2 and S3. The mean
consumption of MLS in the first and fourth quarters (winter) was
>50% higher than the mean consumption of MLS in the second
and third quarters (summer) in Estonia, Italy and Latvia; >40% in
Belgium, Croatia, and Portugal; and >30% in Germany and
Luxembourg. Clarithromycin consumption was >50% higher in
winter quarters than in summer quarters in Belgium, Croatia,
Estonia, Finland, Hungary, Italy, Latvia and Luxembourg.
Azithromycin consumption was >50% higher in winter quarters
than in summer quarters in Croatia, Estonia, Italy, Latvia,
Luxembourg and Portugal.
Compositional data analysis, 1997–2009
The proportional consumption of long-acting macrolides and
streptogramins significantly increased over time relative to that of
short- and intermediate-acting macrolides and lincosamides. The
proportional consumption of streptogramins did not change sig-
nificantly relative to that of long-acting macrolides. The propor-
tional consumption of intermediate-acting macrolides and
lincosamides significantly increased relative to that of short-acting
macrolides (Table 3).
Trends of proportional consumption in individual countries are
shown in Figure S4. When comparing the composition of macrolide
consumption in 2017 with that in 2009, the proportion of short-
acting macrolides decreased in all participating countries, mainly as
the result of decreasing erythromycin consumption. The largest
decreases were observed for the United Kingdom (#35.47%),
Sweden (#28.01%), Romania (#26.08%; total care data; coverage
in 2009 limited to 30%–40%) and Denmark (#23.15%). The propor-
tion of intermediate-acting macrolides decreased in most of the
participating countries. Decreases >10% were observed for 13 out of
30 participating countries, with the largest decreases observed for
Luxembourg (#28.84%), the Netherlands (#26.12%), Belgium
(#24.07%), Hungary (#22.74%) and France (#20.40%). However,
increases were also observed, with the largest increases being
reported for the United Kingdom (!23.37%), Denmark (!9.80%)
and Lithuania (!4.17%). The proportion of long-acting macrolides
increased in all countries except Slovenia (#3.12%). Increases
>10% were observed for 17 out of 30 participating countries, with
the largest increases observed for Latvia (!29.09%), Belgium
(!25.64%), Iceland (!24.51%), the Netherlands (!24.46%),
Hungary (!24.08%) and Luxembourg (!21.06%).
The proportion of lincosamides increased for most countries,
with increases >10% being reported for Germany (!19.04%),
Sweden (!15.71%), Finland (!13.20%) and Luxembourg
(!11.90%). Streptogramins were only consumed in France, where
their proportion increased (!8.00%).
Discussion
This study describes consumption of MLS in the community in the
EU/EEA and found that the observed increasing trend of consump-
tion of MLS up to 2009 in many countries continued afterwards.
However, in more than half of the countries we observed a lower
consumption of MLS in DDD per 1000 inhabitants per day in 2017
than in 2009. Greece was still, in 2017, the EU/EEA country with the
highest consumption of MLS. We did not observe any important



















































































































Figure 2. Consumption of macrolides, lincosamides and streptogramins (ATC J01F) in the community, expressed in packages per 1000 inhabitants
per day, 20 EU/EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e.
community and hospital sector combined, are used.
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1000 inhabitants per day instead of DDD per 1000 inhabitants per
day as consumption metric.
In 2017, the consumption of MLS ranged from 4.77% in
Sweden to 26.29% in Luxembourg.4 In European countries that
are not part of the ESAC-Net but covered by the WHO Europe
Antimicrobial Medicines Consumption (AMC) Network, the inter-
country variation was less pronounced, i.e. from 4.8% (Kyrgyzstan)
to 15.9% (Russian Federation) of the total (i.e. community and hos-
pital sector combined) consumption.8
Three substances, i.e. clarithromycin, azithromycin and clinda-
mycin, represented more than 90% of the community consump-
tion of MLS in the EU/EEA. For most EU/EEA countries, the
proportional consumption of long-acting macrolides (i.e. azithro-
mycin) increased at the expense of that of the other subgroups.
Only in Norway did the consumption of short-acting macrolides
(i.e. erythromycin) remain predominant. In comparison with
2009,3 spiramycin only represented <1% of the community con-
sumption of MLS in 2017. Given that total macrolide consumption
did not change significantly after 2007, this implies that consump-
tion of one subgroup was merely replaced by consumption of an-
other subgroup, rather than consumption being reduced overall.
Both azithromycin and clarithromycin use have been shown to
increase the proportion of macrolide-resistant streptococci in
healthy volunteers but, while this proportion was higher after
azithromycin use than clarithromycin use, only clarithromycin use
selected for the erm(B) gene that confers high-level macrolide re-
sistance.9 The observed increasing proportional consumption of
azithromycin in the EU/EEA corresponds to that reported for the
USA.10–12 The current European guidelines for the management of
community-acquired lower respiratory tract infections in adults
recommend amoxicillin as first-line therapy with macrolides being
reserved for patients with penicillin allergy and regions where
macrolide resistance in pneumococcal isolates is low.13 Yet, the
seasonal variation in the consumption of MLS in the EU/EEA
remained substantial compared with that of overall antibiotic con-
sumption (ATC J01) and other main groups of antibiotics.4,14–17
While a minimal amount of seasonal variation could be associated
with seasonality in bacterial pathogens, the extent of the observed
seasonality suggests inappropriate prescribing during the winter
in many countries.
In Belgium, maintaining macrolide consumption below a critic-
al threshold was associated with both maintenance of a low
prevalence of macrolide-resistant Streptococcus pyogenes and
emergence of milder resistance mechanisms with lower fitness
costs.18,19 In addition, Megraud et al.20 found a significant associ-
ation between the use of specifically long-acting macrolides and
clarithromycin resistance in Helicobacter pylori. A high rate of
clarithromycin resistance no longer allows for its empirical use as
standard regimen for the treatment of H. pylori infections. Current
antibiotic guidelines for the treatment of H. pylori infections recom-
mend bismuth quadruple therapy (A02BD08) in case of high
macrolide resistance rates.
France is the only country using streptogramins (i.e. pristinamy-
cin). Pristinamycin is included in guidelines for the treatment of
sinusitis, exacerbation of chronic bronchitis, pneumonia and skin
infections, mostly in case of penicillin allergy.21–23 Linking antibiotic
prescribing data with indications for these prescriptions would
be helpful to achieve a better understanding of inter-country
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With the exception of clindamycin, all MLS (ATC J01F) are listed
as Watch or Reserve group antibiotics in the 2019 WHO Access,
Watch or Reserve (AWaRe) classification list.24 The continuous
monitoring of the consumption of MLS in the community can help
to assess the impact of future interventions promoting better use
of these antibiotics.
For a more-detailed discussion on the limitations of the col-
lected data, we refer to the article on antibacterials for systemic
use, included in this series.5 For a discussion on the limitations of
the statistical approach used in this study and potential explana-
tions for the common change-points detected through these
analyses, we refer to the tutorial included in this series.6
In conclusion, the increase in the consumption of MLS in the EU/
EEA ended in 2007, after which consumption of MLS remained sta-
ble. The proportional consumption of long-acting macrolides, i.e.
azithromycin, increased over time during 1997–2017. Seasonal
variation remained high, which suggests that MLS are still
prescribed inappropriately in the community in many countries.
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Figure 3. Estimated trend (solid line) and linear trend (dashed line) of consumption of macrolides, lincosamides and streptogramins (ATC J01F) in
the community based on quarterly data, 25 EU/EEA countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted in-
crease (if positive)/decrease (if negative) in consumption per quarter; b2, predicted difference in slope after versus before the first change-point; b3,
predicted difference in slope after versus before the second change-point; b4, predicted difference in slope after versus before the third change-point;
b0
S, predicted amplitude of the upward winter and downward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative)
of the amplitude of the upward winter and downward summer peak in consumption per quarter; d, shift in timing of the upward winter and down-
ward summer peak from one year to another. An asterisk indicates that the result was statistically significant at significance level 0.05.
Table 3. Change in composition of the consumption of macrolides, linco-
samides and streptogramins (ATC J01F) in the community, expressed in
DDD (ATC/DDD index 2019) per 1000 inhabitants per day, 30 EU/EEA
countries, as a function of time during 1997–2017
SAM IAM LAM J01FF J01FG
SAM #0.1276 #0.1895 #0.1824 #0.2271
IAM 0.1276 #0.0619 #0.0549 #0.0995
LAM 0.1895 0.0619 0.0071 #0.0376
J01FF 0.1824 0.0549 #0.0071 #0.0447
J01FG 0.2271 0.0995 0.0376 0.0447
Values are estimated changes in the log ratio of the row versus column
subgroup of antibiotics with increasing time. Bold type indicates a statis-
tically significant effect; positive values represent an increase and nega-
tive values represent a decrease.
SAM, short-acting macrolides; IAM, intermediate-acting macrolides; LAM,
long-acting macrolides; J01FF, lincosamides; J01FG, streptogramins.
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